Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system
Abstract Background Immune-checkpoint inhibitors (ICIs) emerged as a novel class of drugs for the treatment of a broad spectrum of malignancies. ICIs can produce durable antitumor responses but they are also associated with immune-related adverse events (irAEs). Endocrinopathies have reported as one...
Main Authors: | Yinghong Zhai, Xiaofei Ye, Fangyuan Hu, Jinfang Xu, Xiaojing Guo, Yonglong Zhuang, Jia He |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-019-0754-2 |
Similar Items
Similar Items
-
Immune Checkpoint in Glioblastoma: Promising and Challenging
by: Jing Huang, et al.
Published: (2017-05-01) -
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
by: Xinyu Yan, et al.
Published: (2018-09-01) -
Immune checkpoint‑targeted cancer immunotherapies
by: Julian Swatler, et al.
Published: (2016-01-01) -
Immune Checkpoints and Innovative Therapies in Glioblastoma
by: Massimo Romani, et al.
Published: (2018-10-01) -
The role of immune checkpoint inhibitors in prostate cancer
by: Gabriel Surdacki, et al.
Published: (2019-03-01)